[O-35] 一般演題口演セッション35

[O-35-5] 急性肝性ポルフィリン症へのギボシラン投与: ENVISION試験 36ヶ月の結果

^○足立 智英¹, Manish Thapar², Herbert L Bonkovsky³, Susana Monroy⁴, Gayle Ross⁵, Encarna Guillen-Navarro⁶, Maria Domenica Cappellini⁷, Anna-Elisabeth Minder⁸, Shangbin Liu⁹, Marianne T Sweetser⁹, David J Kuter¹⁰ (1.東京都済生会中央病院 脳神経内科・総合診療内科, 2.Massachusetts General Hospital, Boston, MA, USA, 3.Thomas Jefferson University, Philadelphia, PA, USA, 4.Wake Forest University/North Carolina Baptist Medical Center, Winston-Salem, NC, USA, 5.Instituto Nacional de Pediatria, Mexico City, Mexico, 6.Royal Melbourne Hospital, Melbourne, Victoria, Australia, 7.Medical Genetics Section, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain, and CIBERER-ISCIII, Madrid, Spain, 8.University of Milan, Milan, Italy, 9.Division of Endocrinology, Diabetes and Porphyria, Stadtspital Waid und Triemli, Zurich, Switzerland, 10.Alnylam Pharmaceuticals, Cambridge, MA, USA)